Gilead's Quiet Revolution: Is GILD the Next Big Stock to Soar?
Biotechnology company Gilead Sciences (NASDAQ: GILD ) wasn't a “Magnificent Seven” company or a darling of the financial markets in 2023. Yet, GILD stock deserves a long-overdue rally in 2024.
Gilead CEO On 2024 drug pipeline: Expect results from around two dozen clinical trials
Gilead Sciences CEO Daniel O'Day joins 'Squawk Box' to discuss Gilead's drug pipeline in 2024, the company's HIV treatment, breast cancer drug, and more.
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
In the most recent trading session, Gilead Sciences (GILD) closed at $83.31, indicating a -1.38% shift from the previous trading day.
Gilead's Dividend Growth Potential Looks Phenomenal
Gilead Sciences is recovering from reduced Veklury (remdesivir) revenue following the height of the COVID-19 pandemic. The company, however, is making progress in HIV product sales and oncology, th...
Gilead (GILD), Compugen Collaborate for Immunotherapy Program
Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.
Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?
Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $81.78, denoting a -1.58% change from the preceding trading day.
A Bull Market Is Coming: 1 Stock That Could Rocket 219% Higher in 2024, According to Wall Street
Wall Street analysts following Iovance Biotherapeutics set price targets that suggest the stock can triple your money in 2024. Iovance Biotherapeutics is developing cell-based cancer therapies, and...
5 Dividend Growth Stocks To Consider Buying
Korn Ferry, Gilead Sciences, Qualcomm, Ralph Lauren, and Manpower are identified as five companies with high dividend yields and strong capacity for future dividend increases. Korn Ferry is a leade...
Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock?
Gilead Sciences: The Bull Case Is More Powerful Than You Think
Gilead Sciences Inc. (GILD, Financial) is an American pharmaceutical company specializing in developing and commercializing medicines to treat patients with HIV, large B-cell lymphoma, chronic hepa...
Gilead Sciences, Inc. (GILD) Presents at Piper Sandler 35th Annual Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 9:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Par...
J&J, Gilead, BMS: A look at undervalued dividend payers
Johnson & Johnson NYSE: JNJ, Gilead Sciences Inc. NYSE: GILD and Bristol Myers Squibb Co. NYSE: BMY are among healthcare sector dividend-payers trading at low valuations relative to their earnings.
Gilead Sciences, Inc. (GILD) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 1:20 PM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Parti...
Top 5 U.S. Giants for 2024 That Have Failed to Deliver in 2023
We have narrowed our search to five U.S. corporate giants that have failed to deliver in 2023. These are: PEP, PG, MMM, XOM, GILD.
Related Companies